ASH 2024: J&J’s Tecvayli shows promise in transplant-eligible NDMM patient
The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & Johnson’s (J&J) Darzalex in combination with chemotherapy.
The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & Johnson’s (J&J) Darzalex in combination with chemotherapy.
What's Your Reaction?
